Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05121545 · ClinicalTrials.gov registry record · NA

Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors

A NA study of Melanoma and Sarcoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Active
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT05121545 is a NA study of Melanoma and Sarcoma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 11 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05121545, a NA study of Melanoma and Sarcoma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

This is a single arm, phase I study, evaluating the feasibility, toxicity, and degree of tumor response after novel proton pencil beam scanning (PBS GRID) treatment in patients with bulky tumors that are difficult to manage.

Conditions Studied

Interventions

  • RADIATION Pro-GRID

Study Locations (1)

District of Columbia

  • Sibley Memorial Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2022-04-06
Est. Completion 2026-12
Phase NA

What the Registry Record Tells You About NCT05121545

The ClinicalTrials.gov registry entry for NCT05121545 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Pro-GRID is the first listed.

NCT05121545 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05121545 about?

NCT05121545 is a clinical study titled "Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors". This is a single arm, phase I study, evaluating the feasibility, toxicity, and degree of tumor response after novel proton pencil beam scanning (PBS GRID) treatment in patients with bulky tumors that are difficult to manage.

What is the current status of trial NCT05121545?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 11 participants. The study started on 2022-04-06. Estimated completion is 2026-12.

What conditions does trial NCT05121545 study?

This clinical trial studies the following conditions: Melanoma, Sarcoma.

What interventions are being tested in trial NCT05121545?

The interventions under investigation include: Pro-GRID (RADIATION).

Who is sponsoring clinical trial NCT05121545?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05121545 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.